Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon

QJM: An International Journal of Medicine

Volumn 91, Issue 6, 1998, Pages 393-399

  Kalkner K M ^a   Ronnblom L ^a   Karlsson Parra, A ^a   Bengtsson, M ^a   Olsson, Y ^a   Oberg K ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DNA ANTIBODY; DOUBLE STRANDED DNA; GAMMA INTERFERON; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CARCINOID; CONTROLLED STUDY; FEMALE; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PALLIATIVE THERAPY; PANCREAS TUMOR; POLYMYOSITIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 2642695725     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/91.6.393     Document Type: Article

References (23)

1. Öberg K, Norheim I, Lind E, Alm G, Lundquist G, Wide L, et al. Treatment of malignant carcinoids tumours with human leukocytes interferon: long terms results. Cancer Treat Rep 1986; 70:1297-304.
2. Erikson B, Öberg K, Aim G, Karlsson A, Lundquist G, Andersson T, et al. Treatment of malignant endocrine pancreatic tumours with human leukocytes interferon. Lancet 1986; 2:1307-9.
3. Burman P, Tötterman T, Öberg K, Karlsson A. Thyroid autoimmunity in patients on long-term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 1986; 63:1086-90.
4. Wandl UB, Nagel Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M, Seeber S, Niederle N. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992; 65:70-4.
5. Flores A, Olivé A, Feliu E, Tena X. Systemic lupus erythematosus following interferon therapy. Br J Rheumatol 1994; 33:787-92.
6. Rönnblom L, Alm G, Öberg K. Autoimmunity after alpha interferon-therapy for malignant carcinoid tumours. Ann Internal Med 1991; 115:178-83.
7. Rönnblom L, Alm G, Öberg K. Possible induction of systemic lupus erythematosus by interferon-alfa treatment in a patient with maliginant carcinoid tumour. J Intern Med 1990; 227:207-21.
8. Schilling P, Kurzrock R, Kantarajian H, Gutterman J, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991; 68:1536-7.
9. McSweeney EN, Addison IE, Worman CP, Isenberg DA, Goldstone AH. Auto-antibody induction in patients treated with recombinant alpha interferon. Br J Haematol 1993; 85:77-83.
10. Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995; 132:587-93.
11. Tan EM. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 1982; 33:167-240.
12. Bankhurst A. Interferons and systemic lupus erythematosus. J Rheumatol 1987; 14(Suppl):63-7.
13. Kim T, Kanayama Y, Negoro M, Okamura T, Takeda T, Inone T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987; 70:562-9.
14. Ehrenstein M, McSweeney E, Swana M, Worman C, Goldstone A, Isenberg D. Appearance of anti-DNA antibodies in patients treated with interferon-α. Arthritis Rheum 1993; 36:279-80.
15. Austin HA, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, et al. Prognostic factors in lupus nephritis: contribution of renal histologic data. Am J Med 1983; 75:382-91.
16. Jacob L, Lety M-A, Choquette D, Viard J-P, Jacob F, Louvard D, et al. Presence of antibodies against a cell-surface protein, cross-reactive with DNA, in systemic lupus erythematosus: A marker of disease. Proc Natl Acad Sci 1987; 84:2956-9.
17. Schattner A, Duggan D, Naparstek Y, Schwarts RS. Effects of alpha-interferon on the expression of a lupus idiotype in normal humans. Clin Immunol Immunopathol 1986; 38:327-36.
18. Jewell AP, Worman CP, Lydyard PM, Yong KL, Giles FJ, Goldstone AH. Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br J Haematol 1994; 88:268-74.
19. Gatenby PA, Irvine M. The bcl-2 proto-oncogene is overexpressed in systemic lupus erythematosus. J Autoimmun 1994; 7:623-31.
20. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams J M, Cory S, Harris AW. Enforced bcl-2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991; 88:8661-5.
21. Tiwari J, Terasaki P. HLA and disease associations. New York, Springer-Verlag, 1985.
22. Talal N. Autoimmunity and sex revisited. Clin Immunol Immunopathol 1989; 53:355-7.
23. DeMaeyer-Guignard J. Effects of interferon on cell-mediated immunity as manifested by delayed hypersensitivity and allograft rejection. In: Vilcek J, DeMaeyer E, eds. Interferon, vol 2: Interferons and the Immune System. Amsterdam, Elsevier, 1984:131-45.